API Holdings takes 51% of Thyrocare via Docon merger
What's the deal? API HoldingsDealroom has a profile for this one. Try Dealroom → has acquired a 51.02% controlling stake in diagnostics chain Thyrocare TechnologiesDealroom has a profile for this one. Try Dealroom → after absorbing Docon TechnologiesDealroom has a profile for this one. Try Dealroom → through an amalgamation scheme. The transfer covers 81,200,000 equity shares of Thyrocare's paid-up capital.
Why now? The National Company Law Tribunal, Mumbai Bench, sanctioned the scheme on August 31, 2026. It became effective on September 03, 2026.
What changes? Docon was folded into API Holdings, transferring all of its assets, liabilities, and obligations — including its entire Thyrocare shareholding — to the parent. The stake now vests directly with API Holdings.
Notably, the aggregate holding of Thyrocare's promoter and promoter group stays unchanged after the internal restructuring.
The signal: The move consolidates Thyrocare's control under API Holdings, tightening the ownership structure across a company that anchors its diagnostics footprint. The disclosure was filed under Regulation 29(1) of India's Substantial Acquisition of Shares and Takeovers rules.
Read more: investywise.com
Image credit: Generated with Gemini
